Depo-Provera Class Action Lawsuit 2025 Guide: Brain Tumor Risks, Settlements & Filing Steps

Who Qualifies for a Depo-Provera Lawsuit

• Women diagnosed with intracranial meningioma or other brain tumors after long-term Depo-Provera injections;
• Medical records linking Depo-Provera use to tumor diagnosis (imaging, pathology, surgical reports);
• Evidence of Depo-Provera prescriptions, pharmacy records, or clinic injection logs;
• Wrongful death claims by surviving family members where Depo-Provera use allegedly contributed to a fatal tumor;
• Potential monitoring claims for those exposed long-term seeking medical surveillance.

Brain Tumor Risks & Side Effects

• Meningiomas: benign or malignant brain tumors linked to synthetic progestins;
• Neurological symptoms: headaches, vision problems, seizures, dizziness, cognitive impairment;
• Psychological harm: anxiety, depression, trauma from invasive surgery;
• Fatal outcomes: lawsuits allege sudden deaths from hemorrhage due to undiagnosed tumors;
• Alternative dosage questions: plaintiffs argue Pfizer ignored safer low-dose formulations.

Settlement Outlook & Value Factors

No global settlement has been reached, but factors influencing potential payout include:

• Severity of injury: tumor size, surgeries, neurological deficits;
• Proof of use: length of Depo-Provera exposure and medical corroboration;
• Causation evidence: studies showing higher tumor risks with prolonged Depo use;
• Wrongful death: claims tied to fatal hemorrhages or sudden tumor growth;
• Venue: federal MDL vs. state mass tort programs.

Educational only — individual results vary; no outcome guaranteed.

Deadlines to File (Statutes of Limitations)

Deadlines vary by state and may be extended for latent injuries like tumors that manifest years after use. Some revival statutes may reopen expired claims. Speak with an attorney promptly to preserve rights.

Depo-Provera Lawsuit Updates™

Last updated 2025.

• July 25, 2025: Litigation raises dosage concerns about Pfizer’s 150 mg formulation and whether safer low-dose options were ignored.
• July 23, 2025: Nebraska lawsuit filed — woman alleges prolonged Depo-Provera use led to an intracranial meningioma requiring brain surgery.
• July 18, 2025: State filings rise: California (11 active), New York (61), with additional suits in PA, IL, NM, and DE.
• July 16, 2025: Court strictly enforces plaintiff questionnaire deadlines in MDL; noncompliant plaintiffs risk dismissal.
• July 14, 2025: Medical monitoring class simplified — only proof of Depo use required at questionnaire stage.
• July 2, 2025: Wrongful death case filed after autopsy linked fatal hemorrhage to Depo-Provera-related meningioma.
• June 19, 2025: Amended scheduling order sets preemption briefing to conclude Sept 29, 2025, with causation discovery extending into 2026.
• June 13, 2025: Massachusetts lawsuit filed alleging brain tumor and ongoing neurological harm.
• June 10, 2025: Judge Rodgers sets hearing on Pfizer’s preemption motion for Sept 29, 2025.
• June 2, 2025: MDL grows to 348 cases, up 20% in a month.

Get your free confidential review

How the Lawsuit Process Works

1. Intake: collect prescription records, imaging, and diagnosis reports;
2. Filing: complaint filed in MDL (N.D. Florida) or state court;
3. Discovery: expert review of studies, label history, Pfizer internal documents;
4. Pretrial motions: including preemption challenges and causation rulings;
5. Resolution: settlement or bellwether trial outcomes.

Depo-Provera Lawsuit FAQs

Sources & Safety Standards

• University of British Columbia studies on Depo-Provera & meningioma risk
• FDA & EMA regulatory filings
• MDL case management orders and filings